Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19.
Identifieur interne : 001134 ( Main/Exploration ); précédent : 001133; suivant : 001135Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19.
Auteurs : Asl Gelincik [Turquie] ; Knut Brockow [Allemagne] ; Gülfem E. Çelik [Turquie] ; Inmaculada Do A [Espagne] ; Cristobalina Mayorga [Espagne] ; Antonino Romano [Italie] ; Özge Soyer [Turquie] ; Marina Atanaskovic-Markovic [Serbie] ; Annick Barbaud [France] ; Maria Jose Torres [Espagne]Source :
- Allergy [ 1398-9995 ] ; 2020.
Abstract
Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.
DOI: 10.1111/all.14439
PubMed: 32511784
PubMed Central: PMC7300843
Affiliations:
- Allemagne, Espagne, France, Italie, Serbie, Turquie
- Bavière, District de Haute-Bavière, Île-de-France
- Munich, Paris
- Université Louis-et-Maximilien de Munich
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19.</title><author><name sortKey="Gelincik, Asl" sort="Gelincik, Asl" uniqKey="Gelincik A" first="Asl" last="Gelincik">Asl Gelincik</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Brockow, Knut" sort="Brockow, Knut" uniqKey="Brockow K" first="Knut" last="Brockow">Knut Brockow</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Celik, Gulfem E" sort="Celik, Gulfem E" uniqKey="Celik G" first="Gülfem E" last="Çelik">Gülfem E. Çelik</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chest Diseases, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Chest Diseases, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Do A, Inmaculada" sort="Do A, Inmaculada" uniqKey="Do A I" first="Inmaculada" last="Do A">Inmaculada Do A</name><affiliation wicri:level="1"><nlm:affiliation>Allergy Unit, Hospital Regional Universitario de Málaga-ARADyAL, Málaga, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Allergy Unit, Hospital Regional Universitario de Málaga-ARADyAL, Málaga</wicri:regionArea><wicri:noRegion>Málaga</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA-ARADyAL, Málaga, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA-ARADyAL, Málaga</wicri:regionArea><wicri:noRegion>Málaga</wicri:noRegion></affiliation></author><author><name sortKey="Mayorga, Cristobalina" sort="Mayorga, Cristobalina" uniqKey="Mayorga C" first="Cristobalina" last="Mayorga">Cristobalina Mayorga</name><affiliation wicri:level="1"><nlm:affiliation>Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA-ARADyAL, Malaga, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA-ARADyAL, Malaga</wicri:regionArea><wicri:noRegion>Malaga</wicri:noRegion></affiliation></author><author><name sortKey="Romano, Antonino" sort="Romano, Antonino" uniqKey="Romano A" first="Antonino" last="Romano">Antonino Romano</name><affiliation wicri:level="1"><nlm:affiliation>IRCCS Oasi Maria S.S., Troina, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS Oasi Maria S.S., Troina</wicri:regionArea><wicri:noRegion>Troina</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Fondazione Mediterranea G.B. Morgagni, Catania, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Fondazione Mediterranea G.B. Morgagni, Catania</wicri:regionArea><wicri:noRegion>Catania</wicri:noRegion></affiliation></author><author><name sortKey="Soyer, Ozge" sort="Soyer, Ozge" uniqKey="Soyer O" first="Özge" last="Soyer">Özge Soyer</name><affiliation wicri:level="1"><nlm:affiliation>Pediatric Allergy Department, Hacettepe University School of Medicine, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Pediatric Allergy Department, Hacettepe University School of Medicine, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Atanaskovic Markovic, Marina" sort="Atanaskovic Markovic, Marina" uniqKey="Atanaskovic Markovic M" first="Marina" last="Atanaskovic-Markovic">Marina Atanaskovic-Markovic</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, University Children's Hospital, University of Belgrade, Belgrade, Serbia.</nlm:affiliation><country xml:lang="fr">Serbie</country><wicri:regionArea>Faculty of Medicine, University Children's Hospital, University of Belgrade, Belgrade</wicri:regionArea><wicri:noRegion>Belgrade</wicri:noRegion></affiliation></author><author><name sortKey="Barbaud, Annick" sort="Barbaud, Annick" uniqKey="Barbaud A" first="Annick" last="Barbaud">Annick Barbaud</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology and Allergology, Tenon Hospital (AP-HP), Sorbonne Universities, Pierre et Marie Curie University, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology and Allergology, Tenon Hospital (AP-HP), Sorbonne Universities, Pierre et Marie Curie University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Sorbonne Université, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Sorbonne Université, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Torres, Maria Jose" sort="Torres, Maria Jose" uniqKey="Torres M" first="Maria Jose" last="Torres">Maria Jose Torres</name><affiliation wicri:level="1"><nlm:affiliation>Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-BIONAND-ARADyAL, Malaga, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-BIONAND-ARADyAL, Malaga</wicri:regionArea><wicri:noRegion>Malaga</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32511784</idno><idno type="pmid">32511784</idno><idno type="doi">10.1111/all.14439</idno><idno type="pmc">PMC7300843</idno><idno type="wicri:Area/Main/Corpus">000F05</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F05</idno><idno type="wicri:Area/Main/Curation">000F05</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000F05</idno><idno type="wicri:Area/Main/Exploration">000F05</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19.</title><author><name sortKey="Gelincik, Asl" sort="Gelincik, Asl" uniqKey="Gelincik A" first="Asl" last="Gelincik">Asl Gelincik</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Brockow, Knut" sort="Brockow, Knut" uniqKey="Brockow K" first="Knut" last="Brockow">Knut Brockow</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Celik, Gulfem E" sort="Celik, Gulfem E" uniqKey="Celik G" first="Gülfem E" last="Çelik">Gülfem E. Çelik</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chest Diseases, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Chest Diseases, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Do A, Inmaculada" sort="Do A, Inmaculada" uniqKey="Do A I" first="Inmaculada" last="Do A">Inmaculada Do A</name><affiliation wicri:level="1"><nlm:affiliation>Allergy Unit, Hospital Regional Universitario de Málaga-ARADyAL, Málaga, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Allergy Unit, Hospital Regional Universitario de Málaga-ARADyAL, Málaga</wicri:regionArea><wicri:noRegion>Málaga</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA-ARADyAL, Málaga, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA-ARADyAL, Málaga</wicri:regionArea><wicri:noRegion>Málaga</wicri:noRegion></affiliation></author><author><name sortKey="Mayorga, Cristobalina" sort="Mayorga, Cristobalina" uniqKey="Mayorga C" first="Cristobalina" last="Mayorga">Cristobalina Mayorga</name><affiliation wicri:level="1"><nlm:affiliation>Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA-ARADyAL, Malaga, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA-ARADyAL, Malaga</wicri:regionArea><wicri:noRegion>Malaga</wicri:noRegion></affiliation></author><author><name sortKey="Romano, Antonino" sort="Romano, Antonino" uniqKey="Romano A" first="Antonino" last="Romano">Antonino Romano</name><affiliation wicri:level="1"><nlm:affiliation>IRCCS Oasi Maria S.S., Troina, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS Oasi Maria S.S., Troina</wicri:regionArea><wicri:noRegion>Troina</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Fondazione Mediterranea G.B. Morgagni, Catania, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Fondazione Mediterranea G.B. Morgagni, Catania</wicri:regionArea><wicri:noRegion>Catania</wicri:noRegion></affiliation></author><author><name sortKey="Soyer, Ozge" sort="Soyer, Ozge" uniqKey="Soyer O" first="Özge" last="Soyer">Özge Soyer</name><affiliation wicri:level="1"><nlm:affiliation>Pediatric Allergy Department, Hacettepe University School of Medicine, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Pediatric Allergy Department, Hacettepe University School of Medicine, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name sortKey="Atanaskovic Markovic, Marina" sort="Atanaskovic Markovic, Marina" uniqKey="Atanaskovic Markovic M" first="Marina" last="Atanaskovic-Markovic">Marina Atanaskovic-Markovic</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, University Children's Hospital, University of Belgrade, Belgrade, Serbia.</nlm:affiliation><country xml:lang="fr">Serbie</country><wicri:regionArea>Faculty of Medicine, University Children's Hospital, University of Belgrade, Belgrade</wicri:regionArea><wicri:noRegion>Belgrade</wicri:noRegion></affiliation></author><author><name sortKey="Barbaud, Annick" sort="Barbaud, Annick" uniqKey="Barbaud A" first="Annick" last="Barbaud">Annick Barbaud</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology and Allergology, Tenon Hospital (AP-HP), Sorbonne Universities, Pierre et Marie Curie University, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology and Allergology, Tenon Hospital (AP-HP), Sorbonne Universities, Pierre et Marie Curie University, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Sorbonne Université, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Sorbonne Université, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Torres, Maria Jose" sort="Torres, Maria Jose" uniqKey="Torres M" first="Maria Jose" last="Torres">Maria Jose Torres</name><affiliation wicri:level="1"><nlm:affiliation>Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-BIONAND-ARADyAL, Malaga, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-BIONAND-ARADyAL, Malaga</wicri:regionArea><wicri:noRegion>Malaga</wicri:noRegion></affiliation></author></analytic><series><title level="j">Allergy</title><idno type="eISSN">1398-9995</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32511784</PMID><DateRevised><Year>2020</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1398-9995</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Allergy</Title><ISOAbbreviation>Allergy</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/all.14439</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.</AbstractText><CopyrightInformation>© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gelincik</LastName><ForeName>Aslı</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3524-9952</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brockow</LastName><ForeName>Knut</ForeName><Initials>K</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-2775-3681</Identifier><AffiliationInfo><Affiliation>Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Çelik</LastName><ForeName>Gülfem E</ForeName><Initials>GE</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8654-513X</Identifier><AffiliationInfo><Affiliation>Department of Chest Diseases, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doña</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5309-4878</Identifier><AffiliationInfo><Affiliation>Allergy Unit, Hospital Regional Universitario de Málaga-ARADyAL, Málaga, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA-ARADyAL, Málaga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayorga</LastName><ForeName>Cristobalina</ForeName><Initials>C</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8852-8077</Identifier><AffiliationInfo><Affiliation>Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA-ARADyAL, Malaga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romano</LastName><ForeName>Antonino</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5029-4372</Identifier><AffiliationInfo><Affiliation>IRCCS Oasi Maria S.S., Troina, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondazione Mediterranea G.B. Morgagni, Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soyer</LastName><ForeName>Özge</ForeName><Initials>Ö</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7444-251X</Identifier><AffiliationInfo><Affiliation>Pediatric Allergy Department, Hacettepe University School of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atanaskovic-Markovic</LastName><ForeName>Marina</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1354-6072</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University Children's Hospital, University of Belgrade, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbaud</LastName><ForeName>Annick</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8889-1589</Identifier><AffiliationInfo><Affiliation>Department of Dermatology and Allergology, Tenon Hospital (AP-HP), Sorbonne Universities, Pierre et Marie Curie University, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Sorbonne Université, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Maria Jose</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5228-471X</Identifier><AffiliationInfo><Affiliation>Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-BIONAND-ARADyAL, Malaga, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Allergy</MedlineTA><NlmUniqueID>7804028</NlmUniqueID><ISSNLinking>0105-4538</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">desensitization</Keyword><Keyword MajorTopicYN="N">drug hypersensitivity reactions</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32511784</ArticleId><ArticleId IdType="doi">10.1111/all.14439</ArticleId><ArticleId IdType="pmc">PMC7300843</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Organization WH. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance V 1.2. 2020.</Citation></Reference><Reference><Citation>Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease 2019. Allergy 2020. https://doi.org/10.1111/all.14289</Citation></Reference><Reference><Citation>Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26(4):502-505.</Citation></Reference><Reference><Citation>Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020;34(5):e212-e213.</Citation></Reference><Reference><Citation>Monteagudo LA, Boothby A, Gertner E. Continuous intravenous Anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol. 2020;2(5):276-282.</Citation></Reference><Reference><Citation>Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020;55(5):105954.</Citation></Reference><Reference><Citation>Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med. 2020;14(2):126-135.</Citation></Reference><Reference><Citation>Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824-1836.</Citation></Reference><Reference><Citation>Du YX, Chen XP. Favipiravir: pharmacokinetics and Concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020.</Citation></Reference><Reference><Citation>Health TMo. Turkish Ministry of Health COVID-19 Guideline 14.04.2020. 2020.</Citation></Reference><Reference><Citation>Direzione Generale Cura della Persona SeW. Indirizzi terapeutici della Regione E-R per il trattamento della infezione da SARS-CoV2 (COVID-19). 2020.</Citation></Reference><Reference><Citation>Garvey LH, Ebo DG, Mertes PM, et al. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions. Allergy. 2019;74(10):1872-1884.</Citation></Reference><Reference><Citation>Romano A, Atanaskovic-Markovic M, Barbaud A, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy. 2019;75(6):1300-1315.</Citation></Reference><Reference><Citation>Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003;58(9):854-863.</Citation></Reference><Reference><Citation>Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy. 2019;74(1):14-27.</Citation></Reference><Reference><Citation>Gomes ER, Brockow K, Kuyucu S, et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy. 2016;71(2):149-161.</Citation></Reference><Reference><Citation>Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702-712.</Citation></Reference><Reference><Citation>Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2016;71(8):1103-1134.</Citation></Reference><Reference><Citation>Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy. 2010;65(11):1357-1366.</Citation></Reference><Reference><Citation>Scherer K, Brockow K, Aberer W, et al. Desensitization in delayed drug hypersensitivity reactions - an EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013;68(7):844-852.</Citation></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.</Citation></Reference><Reference><Citation>Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19163</Citation></Reference><Reference><Citation>Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16472</Citation></Reference><Reference><Citation>Hunt M, Koziatek C. A case of COVID-19 pneumonia in a young male with full body rash as a presenting symptom. Clin Pract Cases Emerg Med. 2020;4(2):219-221.</Citation></Reference><Reference><Citation>Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020;83(1):280-285.</Citation></Reference><Reference><Citation>Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: A diagnostic clue? Pediatr Dermatol. 2020. https://doi.org/10.1111/pde.14201</Citation></Reference><Reference><Citation>Verdoni L, Mazza A, Gervasoni A. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771-1778.</Citation></Reference><Reference><Citation>Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607-1608.</Citation></Reference><Reference><Citation>Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr. 2020;10(6):537-540. pii: hpeds.2020-0123</Citation></Reference><Reference><Citation>Jimenez-Cauhe J, Ortega-Quijano D, Prieto-Barrios M, Moreno-Arrones OM, Fernandez-Nieto D. Reply to "COVID-19 can present with a rash and be mistaken for Dengue": Petechial rash in a patient with COVID-19 infection. J Am Acad Dermatol. 2020;S0190-9622(20)30556-9.</Citation></Reference><Reference><Citation>Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson RM. Comment on "Cutaneous manifestations in COVID-19: a first perspective " by Recalcati S. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16519</Citation></Reference><Reference><Citation>Gianotti R, Veraldi S, Recalcati S, et al. Cutaneous Clinico-Pathological Findings in three COVID-19-Positive Patients Observed in the Metropolitan Area of Milan, Italy. Acta Derm Venereol. 2020;100(8):adv00124.</Citation></Reference><Reference><Citation>Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol. 2020;82(5):e177.</Citation></Reference><Reference><Citation>Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020;S0190-9622(20)30558-2.</Citation></Reference><Reference><Citation>Kolivras A, Dehavay F, Delplace D, et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathological findings. JAAD Case Rep. 2020;6:489-492.</Citation></Reference><Reference><Citation>Mazzotta F, Troccoli T, Bonifazi E. A new vasculitis at the time of COVID-19. Eur J Pediatr Dermatol - pd online. 2020;30(2):75-78.</Citation></Reference><Reference><Citation>Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, et al. Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol. 2020;S0190-9622(20):30996-8.</Citation></Reference><Reference><Citation>Zhang Y, Cao W, Xiao M, et al. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi 2020;41:E006.</Citation></Reference><Reference><Citation>Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1-13.</Citation></Reference><Reference><Citation>Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020;55(5):105955.</Citation></Reference><Reference><Citation>Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150.</Citation></Reference><Reference><Citation>Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436-443.</Citation></Reference><Reference><Citation>Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV- 2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem. 2020;27.</Citation></Reference><Reference><Citation>Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020;44:e40.</Citation></Reference><Reference><Citation>Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545.</Citation></Reference><Reference><Citation>Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1153-1162.</Citation></Reference><Reference><Citation>Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19. N Engl J Med. 2020;382(19):1787-1799.</Citation></Reference><Reference><Citation>Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007;370(9581):49-58.</Citation></Reference><Reference><Citation>Zuo W, Wen LP, Li J, Mei D, Fu Q, Zhang B. Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report. Medicine (Baltimore). 2019;98(19):e15553.</Citation></Reference><Reference><Citation>Gonzalez-Ramos J, Lamas C, Bellon T, et al. Oseltamivir-induced toxic epidermal necrolysis in a patient with Cushing's disease. Indian J Dermatol Venereol Leprol. 2019.</Citation></Reference><Reference><Citation>Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020;382(24):2327-2336.</Citation></Reference><Reference><Citation>Brillanti S, Mazzella G, Roda E. Ribavirin for chronic hepatitis C: and the mystery goes on. Dig Liver Dis. 2011;43(6):425-430.</Citation></Reference><Reference><Citation>Lorcy S, Gaudy-Marqueste C, Botta D, et al. Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study. Ann Dermatol Venereol. 2016;143(5):336-346.</Citation></Reference><Reference><Citation>Patrk I, Morovic M, Markulin A, Patrk J. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin. Dermatology. 2014;228(1):42-46.</Citation></Reference><Reference><Citation>Brok J, Gluud LL, Gluud C. Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitic C - an updated Cochrane review. Aliment Pharmacol Ther. 2010;32(7):840-850.</Citation></Reference><Reference><Citation>Barreira P, Cadinha S, Malheiro D, da Silva JP. Delayed hypersensitivity to ribavirin confirmed by provocation test. J Investig Allergol Clin Immunol. 2014;24(6):441-442.</Citation></Reference><Reference><Citation>Shindo M, Terai I. Adverse skin reactions due to ribavirin in hepatitis C combination therapy with pegylated interferon-alpha2a. Case Rep Dermatol. 2013;5(3):379-381.</Citation></Reference><Reference><Citation>Ladd AM, Martel-Laferriere V, Dieterich D. Successful desensitization to ribavirin in a patient with chronic hepatitis C. J Clin Gastroenterol. 2012;46(8):716-717.</Citation></Reference><Reference><Citation>Toker O, Tal Y, Daher S, Shalit M. Ribavirin desensitization in chronic hepatitis C. Isr Med Assoc J. 2015;17(9):583-584.</Citation></Reference><Reference><Citation>Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother. 2002;36(7-8):1193-1203.</Citation></Reference><Reference><Citation>Ghosn J, Duvivier C, Tubiana R, Katlama C, Caumes E. Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir. Clin Infect Dis. 2005;41(9):1360-1361.</Citation></Reference><Reference><Citation>Echeverria P, Negredo E, Carosi G, et al. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naive patients: a 48-week, multicentre, randomized study (Lake Study). Antiviral Res. 2010;85(2):403-408.</Citation></Reference><Reference><Citation>Sun L, Deng X, Chen X, et al. Incidence of adverse drug reactions in COVID-10 patients in China: An active monitoring study by hospital pharmacovigilance system. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1866</Citation></Reference><Reference><Citation>Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46(1):24-31.</Citation></Reference><Reference><Citation>Buijs BS, van den Berk GE, Boateng CP, Hoepelman AI, van Maarseveen EM, Arends JE. Cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS. 2015;29(7):785-791.</Citation></Reference><Reference><Citation>Marcos Bravo MC, Ocampo Hermida A, Martinez Vilela J, et al. Hypersensitivity reaction to darunavir and desensitization protocol. J Investig Allergol Clin Immunol. 2009;19(3):250-251.</Citation></Reference><Reference><Citation>Lorber M, Haddad S. Hypersensitivity and desensitization to darunavir in a case of HIV infection with triple-class drug resistance: case description and review of the literature. J Int Assoc Provid AIDS Care. 2013;12(6):378-379.</Citation></Reference><Reference><Citation>Hirschfeld G, Weber L, Renkl A, Scharffetter-Kochanek K, Weiss JM. Anaphylaxis after Oseltamivir (Tamiflu) therapy in a patient with sensitization to star anise and celery-carrot-mugwort-spice syndrome. Allergy. 2008;63(2):243-244.</Citation></Reference><Reference><Citation>Tran DH, Sugamata R, Hirose T, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo). 2019;72(10):759-768.</Citation></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;105949.</Citation></Reference><Reference><Citation>Araujo L, Demoly P. Macrolides allergy. Curr Pharm Des. 2008;14(27):2840-2862.</Citation></Reference><Reference><Citation>Mori F, Pecorari L, Pantano S, et al. Azithromycin anaphylaxis in children. Int J Immunopathol Pharmacol. 2014;27(1):121-126.</Citation></Reference><Reference><Citation>Barni S, Butti D, Mori F, et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides. J Investig Allergol Clin Immunol. 2015;25(2):128-132.</Citation></Reference><Reference><Citation>Schissel DJ, Singer D, David-Bajar K. Azithromycin eruption in infectious mononucleosis: a proposed mechanism of interaction. Cutis. 2000;65(3):163-166.</Citation></Reference><Reference><Citation>Milkovic-Kraus S, Macan J, Kanceljak-Macan B. Occupational allergic contact dermatitis from azithromycin in pharmaceutical workers: a case series. Contact Dermatitis. 2007;56(2):99-102.</Citation></Reference><Reference><Citation>Mendes-Bastos P, Bras S, Amaro C, Cardoso J. Non-occupational allergic contact dermatitis caused by azithromycin in an eye solution. J Dtsch Dermatol Ges. 2014;12(8):729-730.</Citation></Reference><Reference><Citation>An I, Demir V, Akdeniz S. Fixed drug eruption probably induced by azithromycin. Australas J Dermatol. 2017;58(4):e253-e254.</Citation></Reference><Reference><Citation>Campanon-Toro MV, Sierra O, Moreno E, Sobrino-Garcia M, Gracia-Bara MT, Davila I. Acute generalized exanthematous pustulosis (AGEP) induced by azithromycin. Contact Dermatitis. 2017;76(6):363-364.</Citation></Reference><Reference><Citation>Sriratanaviriyakul N, Nguyen LP, Henderson MC, Albertson TE. Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) syndrome associated with azithromycin presenting like septic shock: a case report. J Med Case Rep. 2014;8:332.</Citation></Reference><Reference><Citation>Aihara Y, Ito S, Kobayashi Y, Aihara M. Stevens-Johnson syndrome associated with azithromycin followed by transient reactivation of herpes simplex virus infection. Allergy. 2004;59(1):118.</Citation></Reference><Reference><Citation>Xu L, Zhu Y, Yu J, Deng M, Zhu X. Nursing care of a boy seriously infected with Steven-Johnson syndrome after treatment with azithromycin: A case report and literature review. Medicine (Baltimore). 2018;97(1):e9112.</Citation></Reference><Reference><Citation>Odemis E, Kalyoncu M, Okten A, Yildiz K. Azithromycin-induced leukocytoclastic vasculitis. J Rheumatol. 2003;30(10):2292.</Citation></Reference><Reference><Citation>Pursnani A, Yee H, Slater W, Sarswat N. Hypersensitivity myocarditis associated with azithromycin exposure. Ann Intern Med. 2009;150(3):225-226.</Citation></Reference><Reference><Citation>Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol. 2003;112(3):629-630.</Citation></Reference><Reference><Citation>Won HK, Yang MS, Song WJ, et al. Determination of nonirritating concentrations of antibiotics for intradermal skin tests in Korean adults. J Allergy Clin Immunol Pract 2017;5(1):192-194. e192.</Citation></Reference><Reference><Citation>Seitz CS, Brocker EB, Trautmann A. Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing. Allergol Immunopathol (Madr) 2011;39(4):193-199.</Citation></Reference><Reference><Citation>Unal D, Demir S, Gelincik A, et al. Diagnostic value of oral challenge testing in the diagnosis of macrolide hypersensitivity. J Allergy Clin Immunol Pract 2018;6:521-527.</Citation></Reference><Reference><Citation>Staso P, Leonov A. Drug desensitization in 17-year-old male with Mast Cell Activation Syndrome, pneumonia, and antibiotic hypersensitivities. AME Case Rep 2017;1:7.</Citation></Reference><Reference><Citation>Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J. 2020;postgradmedj-2020-137785.</Citation></Reference><Reference><Citation>Soria A, Barbaud A, Assier H, et al. Cutaneous adverse drug reactions with antimalarials and allergological skin tests. Dermatology 2015;231(4):353-359.</Citation></Reference><Reference><Citation>Matsuda T, Ly NTM, Kambe N, et al. Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work. J Dermatol. 2018;45(3):344-348.</Citation></Reference><Reference><Citation>Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989-996.</Citation></Reference><Reference><Citation>Volpe A, Marchetta A, Caramaschi P, Biasi D, Bambara LM, Arcaro G. Hydroxychloroquine-induced DRESS syndrome. Clin Rheumatol. 2008;27(4):537-539.</Citation></Reference><Reference><Citation>Schmutz JL, Barbaud A, Trechot P. Hydroxychloroquine and DRESS. Ann Dermatol Venereol. 2008;135(12):903.</Citation></Reference><Reference><Citation>Girijala RL, Siddiqi I, Kwak Y, Wright D, Patel DB, Goldberg LH. Pustular DRESS syndrome secondary to hydroxychloroquine with EBV reactivation. J Drugs Dermatol. 2019;18(2):207-209.</Citation></Reference><Reference><Citation>Perez-Ezquerra PR, de Barrio FM, de Castro Martinez FJ, Ruiz Hornillos FJ, Prieto GA. Delayed hypersensitivity to hydroxychloroquine manifested by two different types of cutaneous eruptions in the same patient. Allergol Immunopathol (Madr). 2006;34(4):174-175.</Citation></Reference><Reference><Citation>Phillips-Howard PA, Warwick BJ. Idiosyncratic reaction resembling toxic epidermal necrolysis caused by chloroquine and maloprim. Br Med J (Clin Res Ed). 1988;296(6636):1605.</Citation></Reference><Reference><Citation>Kanny G, Renaudin JM, Lecompte T, Moneret-Vautrin DA. Chloroquine hypersensitivity syndrome. Eur J Intern Med. 2002;13(1):75-76.</Citation></Reference><Reference><Citation>Murphy M, Carmichael AJ. Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol. 2001;26(5):457-458.</Citation></Reference><Reference><Citation>Cameron MC, Word AP, Dominguez A. Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus. Dermatol Online J. 2014;20(11). 13030/qt1q90q0h5</Citation></Reference><Reference><Citation>Lisi P, Assalve D, Hansel K. Phototoxic and photoallergic dermatitis caused by hydroxychloroquine. Contact Dermatitis. 2004;50(4):255-256.</Citation></Reference><Reference><Citation>Meier H, Elsner P, Wuthrich B. Occupationally-induced contact dermatitis and bronchial asthma in a unusual delayed reaction to hydroxychloroquine. Hautarzt. 1999;50(9):665-669.</Citation></Reference><Reference><Citation>Charfi O, Kastalli S, Sahnoun R, Lakhoua G. Hydroxychloroquine-induced acute generalized exanthematous pustulosis with positive patch-testing. Indian J Pharmacol. 2015;47(6):693-694.</Citation></Reference><Reference><Citation>Mates M, Zevin S, Breuer GS, Navon P, Nesher G. Desensitization to hydroxychloroquine-experience of 4 patients. J Rheumatol. 2006;33(4):814-816.</Citation></Reference><Reference><Citation>Caramaschi P, Barbazza R, Tinazzi I, Biasi D. Desensitization to hydroxychloroquine: 4 cases. J Rheumatol. 2011;38(10):2267; author reply 2267.</Citation></Reference><Reference><Citation>Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience. Lupus. 2018;27(5):703-707.</Citation></Reference><Reference><Citation>Barailler H, Milpied B, Chauvel A, et al. Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization. J Allergy Clin Immunol Pract. 2019;7(1):307-308.</Citation></Reference><Reference><Citation>Rowane M, Schend J, Patel J, Hostoffer R Jr. Rapid desensitization of hydroxychloroquine. Ann Allergy Asthma Immunol. 2020;124(1):97-98.</Citation></Reference><Reference><Citation>Donado CD, Diez EM. Successful desensitization for hydroxychloroquine anaphylaxis. J Rheumatol. 2010;37(9):1975-1976.</Citation></Reference><Reference><Citation>Perez-Sanchez N, Esponda-Juarez K, Cimarra Alvarez M, Aleo Lujan E, Toledano Martinez E, Fernandez-Rivas MM. Short desensitization in an adolescent with hydroxychloroquine anaphylaxis. Pediatr Allergy Immunol. 2014;25(8):819-821.</Citation></Reference><Reference><Citation>Rothan HA, Stone S, Natekar J, Kumari P, Arora K, Kumar M.The FDA- approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells. https://www.biorxiv.org/content/10.1101/2020.04.14.041228v1</Citation></Reference><Reference><Citation>Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326(4):905-908.</Citation></Reference><Reference><Citation>Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222.</Citation></Reference><Reference><Citation>Vazquez-Lopez F, Manjon-Haces JA, Perez-Alvarez R, Perez-Oliva N. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment. Br J Dermatol. 2004;150(5):1046-1047; author reply 1047.</Citation></Reference><Reference><Citation>Kerl K, Negro F, Lubbe J. Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin. Br J Dermatol. 2003;149(3):656.</Citation></Reference><Reference><Citation>Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13(7):657-665.</Citation></Reference><Reference><Citation>Milkiewicz P, Yim C, Pache I, Heathcote J. Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon. Can J Gastroenterol. 2005;19(11):677-678.</Citation></Reference><Reference><Citation>Cottoni F, Bolognini S, Deplano A, et al. Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon? Acta Derm Venereol. 2004;84(2):120-123.</Citation></Reference><Reference><Citation>Poreaux C, Bronowicki JP, Debouverie M, Schmutz JL, Waton J, Barbaud A. Clinical allergy. Managing generalized interferon-induced eruptions and the effectiveness of desensitization. Clin Exp Allergy. 2014;44(5):756-764.</Citation></Reference><Reference><Citation>Sidhu-Malik NK, Kaplan AL. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection. J Drugs Dermatol. 2003;2(5):570-573.</Citation></Reference><Reference><Citation>Conroy M, Sewell L, Miller OF, Ferringer T. Interferon-beta injection site reaction: review of the histology and report of a lupus-like pattern. J Am Acad Dermatol. 2008;59(2 Suppl 1):S48-49.</Citation></Reference><Reference><Citation>Brown DL, Login IS, Borish L, Powers PL. An urticarial IgE-mediated reaction to interferon beta-1b. Neurology 2001;56(10):1416-1417.</Citation></Reference><Reference><Citation>Kalpaklioglu FA, Baccioglu Kavut A, Erdemoglu AK. Desensitization in interferon-beta1a allergy: a case report. Int Arch Allergy Immunol. 2009;149(2):178-180.</Citation></Reference><Reference><Citation>Cortellini G, Amadori A, Comandini T, Corvetta A. Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin tests. Eur Ann Allergy Clin Immunol. 2013;45(5):181-182.</Citation></Reference><Reference><Citation>Sakatani A, Doi Y, Matsuda T, et al. Protracted anaphylaxis developed after peginterferon alpha-2a administration for chronic hepatitis C. World J Gastroenterol. 2015;21(9);2826-2829.</Citation></Reference><Reference><Citation>Meller S, Erhardt A, Auci A, Neumann NJ, Homey B. Drug-induced exanthema caused by pegylated interferon-alpha 2b. Hautarzt. 2003;54(10):992-993.</Citation></Reference><Reference><Citation>Taghavi SA, Eshraghian A. Successful interferon desensitization in a patient with chronic hepatitis C infection. World J Gastroenterol. 2009;15(33):4196-4198.</Citation></Reference><Reference><Citation>Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.</Citation></Reference><Reference><Citation>Ngwasiri CA, Abanda MH, Aminde LN. Ivermectin-induced fixed drug eruption in an elderly Cameroonian: a case report. J Med Case Rep. 2018;12(1):254.</Citation></Reference><Reference><Citation>Kerneuzet I, Blind E, Darrieux L, Moreau S, Safa G. Ivermectin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. JAAD Case Rep. 2018;4(6):524-527.</Citation></Reference><Reference><Citation>Aroke D, Tchouakam DN, Awungia AT, Mapoh SY, Ngassa SN, Kadia BM. Ivermectin induced Steven-Johnsons syndrome: case report. BMC Res Notes. 2017;10(1):179.</Citation></Reference><Reference><Citation>Seegobin K, Bueno E, Maharaj S, Ashby T, Brown M, Jones L. Toxic epidermal necrolysis after ivermectin. Am J Emerg Med. 2018;36(5):887-889.</Citation></Reference><Reference><Citation>Kelleni MT. Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management. Pharmacol Res. 2020;30:104874.</Citation></Reference><Reference><Citation>Regnier Galvao V, Castells MC. Hypersensitivity to biological agents- Updated diagnosis, management and treatment. J Allegy Clin Immunol Pract. 2015;3:174-185.</Citation></Reference><Reference><Citation>Nakamura M, Tokura Y. Tocilizumab-induced erythroderma. Eur J Dermatol. 2009;19(3):273-274.</Citation></Reference><Reference><Citation>Yoshiki R, Nakamura M, Tokura Y. Drug eruption induced by IL-6 receptor inhibitor tocilizumab. J Eur Acad Dermatol Venereol. 2010;24(4):495-496.</Citation></Reference><Reference><Citation>Soyer O, Demir S, Bilginer Y, et al. Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases. Pediatr Allergy Immunol. 2019;30(8):833-840.</Citation></Reference><Reference><Citation>Koc R, Sonmez HE, Cakan M, et al. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center. Rheumatol Int. 2020;40(5):771-776.</Citation></Reference><Reference><Citation>Rocchi V, Puxeddu I, Cataldo G, et al. Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis. Rheumatology (Oxford). 2014;53(8):1527-1529.</Citation></Reference><Reference><Citation>Tetu P, Hamelin A, Moguelet P, Barbaud A, Soria A. Management of hypersensitivity reactions to Tocilizumab. Clin Exp Allergy. 2018;48(6):749-752.</Citation></Reference><Reference><Citation>Cortellini G, Mascella F, Simoncelli M, et al. Effective desensitization to tocilizumab in delayed hypersensitivity reaction. Pharmacology. 2018;102(1-2):114-116.</Citation></Reference><Reference><Citation>Ben Said B, Gerfaud-Valentin M, Seve P. Fatal DRESS syndrome under tocilizumab treatment for seronegative polyarthritis. J Allergy Clin Immunol Pract. 2018;6(3):1048-1049.</Citation></Reference><Reference><Citation>Zuelgaray E, Domont F, Peiffer-Smadja N, Saadoun D, Cacoub P. Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms syndrome in adult-onset still disease. Ann Intern Med. 2017;167(2):141-142.</Citation></Reference><Reference><Citation>Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921-1927.</Citation></Reference><Reference><Citation>Izquierdo JH, Bonilla-Abadia F, Ochoa CD, Agualimpia A, Tobon GJ, Canas CA. Acute generalized exanthematous pustulosis due to tocilizumab in a rheumatoid arthritis patient. Case Rep Rheumatol. 2012;2012:517424.</Citation></Reference><Reference><Citation>Yasuoka R, Iwata N, Abe N, et al. Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis. Mod Rheumatol. 2019;29(2):324-327.</Citation></Reference><Reference><Citation>den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis. 2006;65(6):760-762.</Citation></Reference><Reference><Citation>Kaiser C, Knight A, Nordström D, Petterson T, Fransson J, Robertsson EF. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int. 2012;32:295-299. https://doi.org/10.1007/s00296-011-2096-3</Citation></Reference><Reference><Citation>Soyyigit S, Kendirlinan R, Aydin O, Celik GE. Successful desensitization with anakinra in a case with immediate hypersensitivity reaction. Ann Allergy Asthma Immunol. 2014;113(3):325-326.</Citation></Reference><Reference><Citation>Desai D, Goldbach-Mansky R, Milner JD, et al. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacother. 2009;43(5):967-972.</Citation></Reference><Reference><Citation>Yılmaz I, Turk M, Nazik BS. Successful rapid subcutaneous desensitization to anakinra in a case with a severe immediate-type hypersensitivity reaction. Eur Ann Allergy Clin Immunol. 2018;50(2):94-96.</Citation></Reference><Reference><Citation>Emmi G, Silvestri E, Cantarini L, et al. Rapid desensitization to anakinra-related delayed reaction: Need for a standardized protocol. J Dermatol. 2017;44(8):981-982.</Citation></Reference><Reference><Citation>Bendele A, Colloton M, Vrkljan M, Morris J, Sabados K. Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications. J Lab Clin Med. 1995;125(4):493-500.</Citation></Reference><Reference><Citation>Lu CC, Chen MY, Chang YL. Potential therapeutic agents against COVID-19: What we know so far? J Chin Med Assoc. 2020;83(6):534-536. https://doi.org/10.1097/JCMA.0000000000000318</Citation></Reference><Reference><Citation>Wells AF, Parrino J, Mangan EK, et al. Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs. Rheumatol Ther. 2019;6:339-352.</Citation></Reference><Reference><Citation>Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259-268.</Citation></Reference><Reference><Citation>Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020; https://doi.org/10.1016/S1473-3099(20)30262-0</Citation></Reference><Reference><Citation>Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400-402.</Citation></Reference><Reference><Citation>Fournier JB, Cummings F, Cannella J. Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib. Dermatol Online J. 2014;20(10). pii: 13030/qt2jg3q02x.</Citation></Reference><Reference><Citation>Koumaki D, Koumaki V, Lagoudaki E, Bertsias G. Palmoplantar pustulosis-like eruption induced by baricitinib for treatment of rheumatoid athritis. Eur J Case Rep Intern Med. 2019;7(1):001383.</Citation></Reference><Reference><Citation>Doohan BJ, Cranwell WC, Varigos GA, De Cruz R. An urticarial drug eruption caused by tofacitinib for alopecia universalis. Dermatol Ther. 2019;32:e12933.</Citation></Reference><Reference><Citation>Shibata T, Muto J, Hirano Y, et al. Palmoplantar pustulosis-like eruption following tofacitinib therapy for juvenile idiopathic arthritis. Ohshima, JAAD Case Rep. 2019;5:518-521.</Citation></Reference><Reference><Citation>de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011;92:2542-2548. https://doi.org/10.1099/vir.0.034983-0.</Citation></Reference><Reference><Citation>Volcheck GW, Van Dellen RG. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. Ann Allergy Asthma Immunol. 1998;80(2):159-163.</Citation></Reference><Reference><Citation>Kang SY, Sohn KH, Lee JO, Kim SH, Cho SH, Chang YS. Intravenous tacrolimus and cyclosporine induced anaphylaxis: what is next? Asia Pac Allergy. 2015;5(3):181-186.</Citation></Reference><Reference><Citation>Ebo DG, Piel GC, Conraads V, Stevens WJ. IgE-mediated anaphylaxis after first intravenous infusion of cyclosporine. Ann Allergy Asthma Immunol. 2001;87(3):243-245.</Citation></Reference><Reference><Citation>Deftereos SG, Siasos G, Giannopoulos G, et al. The Greek study in the Effects of Colchicine in Covid-19 complications prevention (GRECCO-19 study): rationale and study design. Hellenic J Cardiol J. 2020; S1109-9666(20)30061-0. https://doi.org/10.1016/j.hjc.2020.03.002</Citation></Reference><Reference><Citation>Mochida K, Teramae H, Hamada T. Fixed drug eruption due to colchicine. Dermatology. 1996;192:61.</Citation></Reference><Reference><Citation>Levinger U, Monselise A. Reporting a desensitization protocol for colchicine treatment. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S79.</Citation></Reference><Reference><Citation>Barbaud A, Trechot P, Reichert-Penetrat S, Commun N, Schmutz JL. Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. Contact Dermatitis. 2001;45(5):265-268.</Citation></Reference><Reference><Citation>Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040-4047.</Citation></Reference><Reference><Citation>Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barre syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17(6):519-529.</Citation></Reference><Reference><Citation>Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry. Kidney Int Rep. 2019;4(11):1568-1576.</Citation></Reference><Reference><Citation>Lo R, Alexander S, Moss J, Siddiqi A, Liu A. Eculizumab hypersensitivity and desensitization in a toddler with atypical hemolytic uremic syndrome. J Allergy Clin Immunol Pract. 2019;7(7):2409-2410.</Citation></Reference><Reference><Citation>Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395(10223):473-475.</Citation></Reference><Reference><Citation>Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5(1):18.</Citation></Reference><Reference><Citation>Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-690.</Citation></Reference><Reference><Citation>Ventura MT, Calogiuri GF, Muratore L, et al. Cross-reactivity in cell-mediated and IgE-mediated hypersensitivity to glucocorticoids. Curr Pharm Des. 2006;12(26):3383-3391.</Citation></Reference><Reference><Citation>Baeck M, Marot L, Nicolas JF, Pilette C, Tennstedt D, Goossens A. Allergic hypersensitivity to topical and systemic corticosteroids: a review. Allergy. 2009;64(7):978-994.</Citation></Reference><Reference><Citation>Baker A, Empson M, The R, Fitzharris P. Skin testing for immediate hypersensitivity to corticosteroids: a case series and literature review. Clin Exp Allergy. 2015;45(3):669-676.</Citation></Reference><Reference><Citation>Patel A, Bahna SL. Immediate hypersensitivity reactions to corticosteroids. Ann Allergy Asthma Immunol. 2015;115(3):178-182. e173.</Citation></Reference><Reference><Citation>Aranda A, Mayorga C, Ariza A, et al. IgE-mediated hypersensitivity reactions to methylprednisolone. Allergy. 2010;65(11):1376-1380.</Citation></Reference><Reference><Citation>Venturini M, Lobera T, del Pozo MD, Gonzalez I, Blasco A. Immediate hypersensitivity to corticosteroids. J Investig Allergol Clin Immunol. 2006;16(1):51-56.</Citation></Reference><Reference><Citation>Rachid R, Leslie D, Schneider L, Twarog F. Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition. J Allergy Clin Immunol. 2011;127(2):524-528.</Citation></Reference><Reference><Citation>Li PH, Wagner A, Thomas I, Watts TJ, Rutkowski R, Rutkowski K. Steroid allergy: clinical features and the importance of excipient testing in a diagnostic algorithm. J Allergy Clin Immunol Pract. 2018;6(5):1655-1661.</Citation></Reference><Reference><Citation>Angel-Pereira D, Berges-Gimeno MP, Madrigal-Burgaleta R, Urena-Tavera MA, Zamora-Verduga M, Alvarez-Cuesta E. Successful rapid desensitization to methylprednisolone sodium hemisuccinate: a case report. J Allergy Clin Immunol Pract. 2014;2(3):346-348.</Citation></Reference><Reference><Citation>Guvenir H, Misirlioglu ED, Aydin F, Ece D, Cakar N, Kocabas CN. Successful methylprednisolone desensitization in a pediatric patient. Pediatr Allergy Immunol. 2017;28(3):305-306.</Citation></Reference><Reference><Citation>Barbaud A, Waton J. Systemic allergy to corticosteroids: clinical features and cross reactivity. Curr Pharm Des. 2016;22(45):6825-6831.</Citation></Reference><Reference><Citation>Padial A, Posadas S, Alvarez J, et al. Nonimmediate reactions to systemic corticosteroids suggest an immunological mechanism. Allergy. 2005;60(5):665-670.</Citation></Reference><Reference><Citation>Zhai Z, Li C, Chen Y, et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost. 2020;120:937-948.</Citation></Reference><Reference><Citation>Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy. 2006;61(12):1432-1440.</Citation></Reference><Reference><Citation>Trautmann A, Seitz CS. Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. Immunol Allergy Clin North Am. 2009;29(3):469-480.</Citation></Reference><Reference><Citation>Bank I, Libourel EJ, Middeldorp S, Van Der Meer J, Buller HR. High rate of skin complications due to low-molecular-weight heparins in pregnant women. J Thromb Haemost. 2003;1(4):859-861.</Citation></Reference><Reference><Citation>Tan E, Thompson G, Ekstrom C, Lucas M. Non-immediate heparin and heparinoid cutaneous allergic reactions: a role for fondaparinux. Intern Med J. 2018;48(1):73-77.</Citation></Reference><Reference><Citation>Kim KH, Lynfield Y. Enoxaparin-induced generalized exanthem. Cutis. 2003;72(1):57-60.</Citation></Reference><Reference><Citation>Seitz CS, Brocker EB, Trautmann A. Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance. Dermatol Online J. 2008;14(9):4.</Citation></Reference><Reference><Citation>Rodriguez-Fernandez A, Sanchez-Dominguez M, Torrado-Espanol I, Noguerado-Mellado B, Rojas-Perez-Ezquerra P. Clinical patterns of heparin allergy: cross-reactivity between low-molecular-weight heparins and unfractionated heparins. J Investig Allergol Clin Immunol. 2019;29(2):132-134.</Citation></Reference><Reference><Citation>Ronceray S, Dinulescu M, Le Gall F, Polard E, Dupuy A, Adamski H. Enoxaparin-induced DRESS syndrome. Case Rep Dermatol. 2012;4(3):233-237.</Citation></Reference><Reference><Citation>Bidaki R, Saeidi SA, Zarch MB. Delirious state and agitation following heparin induced Stevens-Johnson syndrome. J Clin Diagn Res. 2017;11(5):VL01.</Citation></Reference><Reference><Citation>Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71(2):247-251.</Citation></Reference><Reference><Citation>Greinacher A. Heparin-Induced Thrombocytopenia. N Engl J Med. 2015;373(19):1883-1884.</Citation></Reference><Reference><Citation>Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710-2715.</Citation></Reference><Reference><Citation>Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin-induced recurrent anaphylaxis. Clin Exp Allergy. 2004;34(12):1916-1918.</Citation></Reference><Reference><Citation>Anders D, Trautmann A. Allergic anaphylaxis due to subcutaneously injected heparin. Allergy Asthma Clin Immunol. 2013;9(1):1.</Citation></Reference><Reference><Citation>Cesana P, Scherer K, Bircher AJ. Immediate type hypersensitivity to Heparins: two case reports and a review of the literature. Int Arch Allergy Immunol. 2016;171(3-4):285-289.</Citation></Reference><Reference><Citation>Leguisamo S, Prados Castano M, Pinero Saavedra M, Cimbollek S. Recurrent anaphylaxis due to enoxaparin. J Invest Allergol Clin Immunol. 2015;25(4):297-299.</Citation></Reference><Reference><Citation>Caballero MR, Fernandez-Benitez M. Allergy to heparin: a new in vitro diagnostic technique. Allergol Immunopathol (Madr). 2003;31(6):324-328.</Citation></Reference><Reference><Citation>Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH. Heparin-induced skin lesions. Lancet. 2012;380(9856):1867-1879.</Citation></Reference><Reference><Citation>Parekh K, Burkhart HM, Hatab A, Ross A, Muller BA. Heparin allergy: successful desensitization for cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005;130(5):1455-1456.</Citation></Reference><Reference><Citation>Patriarca G, Rossi M, Schiavino D, et al. Rush desensitization in heparin hypersensitivity: a case report. Allergy. 1994;49(4):292-294.</Citation></Reference><Reference><Citation>Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol. 2011;72(4):634-646.</Citation></Reference><Reference><Citation>Tonew E, Indulen MK, Dzeguze DR. Antiviral action of dipyridamole and its derivatives against influenza virus A. Acta Virol. 1982;26(3):125-129.</Citation></Reference><Reference><Citation>Fata-Hartley CL, Palmenberg AC. Dipyridamole reversibly inhibits mengovirus RNA replication. J Virol 2005;79(17):11062-11070.</Citation></Reference><Reference><Citation>Liu X, Li Z, Liu S, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B. 2020.</Citation></Reference><Reference><Citation>Salava A, Alanko K, Hyry H. Dipyridamole-induced eczematous drug eruption with positive patch test reaction. Contact Dermatitis. 2012;67(2):103-104.</Citation></Reference><Reference><Citation>Angelides S, Van der Wall H, Freedman SB. Acute reaction to dipyridamole during myocardial scintigraphy. N Engl J Med. 1999;340(5):394.</Citation></Reference><Reference><Citation>Weinmann P, Moretti JL, Leynadier F. Anaphylaxis-like reaction induced by dipyridamole during myocardial scintigraphy. Am J Med. 1994;97(5):488.</Citation></Reference><Reference><Citation>Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74(8):1457-1471.</Citation></Reference><Reference><Citation>Trautmann A, Benoit S, Goebeler M, Stoevesandt J. !Treating through! Decision and follow-up in antibiotic therapy-associated exanthemas. J Allergy Clin Immunol Pract. 2017;5(6):1650-1656.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Espagne</li><li>France</li><li>Italie</li><li>Serbie</li><li>Turquie</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li><li>Île-de-France</li></region><settlement><li>Munich</li><li>Paris</li></settlement><orgName><li>Université Louis-et-Maximilien de Munich</li></orgName></list><tree><country name="Turquie"><noRegion><name sortKey="Gelincik, Asl" sort="Gelincik, Asl" uniqKey="Gelincik A" first="Asl" last="Gelincik">Asl Gelincik</name></noRegion><name sortKey="Celik, Gulfem E" sort="Celik, Gulfem E" uniqKey="Celik G" first="Gülfem E" last="Çelik">Gülfem E. Çelik</name><name sortKey="Soyer, Ozge" sort="Soyer, Ozge" uniqKey="Soyer O" first="Özge" last="Soyer">Özge Soyer</name></country><country name="Allemagne"><region name="Bavière"><name sortKey="Brockow, Knut" sort="Brockow, Knut" uniqKey="Brockow K" first="Knut" last="Brockow">Knut Brockow</name></region></country><country name="Espagne"><noRegion><name sortKey="Do A, Inmaculada" sort="Do A, Inmaculada" uniqKey="Do A I" first="Inmaculada" last="Do A">Inmaculada Do A</name></noRegion><name sortKey="Do A, Inmaculada" sort="Do A, Inmaculada" uniqKey="Do A I" first="Inmaculada" last="Do A">Inmaculada Do A</name><name sortKey="Mayorga, Cristobalina" sort="Mayorga, Cristobalina" uniqKey="Mayorga C" first="Cristobalina" last="Mayorga">Cristobalina Mayorga</name><name sortKey="Torres, Maria Jose" sort="Torres, Maria Jose" uniqKey="Torres M" first="Maria Jose" last="Torres">Maria Jose Torres</name></country><country name="Italie"><noRegion><name sortKey="Romano, Antonino" sort="Romano, Antonino" uniqKey="Romano A" first="Antonino" last="Romano">Antonino Romano</name></noRegion><name sortKey="Romano, Antonino" sort="Romano, Antonino" uniqKey="Romano A" first="Antonino" last="Romano">Antonino Romano</name></country><country name="Serbie"><noRegion><name sortKey="Atanaskovic Markovic, Marina" sort="Atanaskovic Markovic, Marina" uniqKey="Atanaskovic Markovic M" first="Marina" last="Atanaskovic-Markovic">Marina Atanaskovic-Markovic</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Barbaud, Annick" sort="Barbaud, Annick" uniqKey="Barbaud A" first="Annick" last="Barbaud">Annick Barbaud</name></region><name sortKey="Barbaud, Annick" sort="Barbaud, Annick" uniqKey="Barbaud A" first="Annick" last="Barbaud">Annick Barbaud</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001134 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001134 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32511784
|texte= Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32511784" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |